You expect more from biomarkers, Tutivia™ delivers.
+ 80% of clinically indication biopsies were performed in the first 60 days.
+ 69% of these early biopsies showed acute rejection (AR).
+ 83% of early biopsies showing AR had a high Tutivia™ risk score.
Tutivia™ is designed to be a single blood test detecting RNA expression changes earlier in the disease course than later markers of injury such as cfDNA.
Tutivia™ can be used as early as the first week after the transplant.
Tutivia™ provides a patient-centric risk score that can be used proactively and demonstrates statistically significant improved performance over serum creatinine while being an independent predictor in combination with serum creatinine.